Program

8th Asian Biologics and Biosimilars Congress


Expert Speakers. Evidence based. Health Care Professionals.

August 10-12, 2017 Beijing, China



Seating is Limited
Register Today!

Conference Secretariat
2360 Corporate Circle, Suite 400 Henderson
NV 89074-7722, USA
Conference Series
Direct: (702) 508-5200 Ext: 8083
Tel: +1 (800) 216 6499
Email: biosimilarsasia@pharmaceuticalconferences.org



Welcome Message

Dear Colleagues, Scientists and Friends,

The Organizing Committee is delighted to invite you to attend the 8th Asian Biosimilars Congress, one of its remarkable pharmaceutical conferences, to be held during August 10-12, 2017 in Beijing, China. The Asian Biosimilars Congress 2017 brings together scientists, researchers, industry and CRO representatives from around the world.

As of December 2016 there were 23 biosimilars marketed in the EU and 4 biosimilars licensed in the USA. As such, the biosimilars market is expected to experience an exponential growth over the coming few years. Many new biologics are making their entry in the pharma market and experiencing a notable rise in their usage compared with the conventional medications.

The 8th Asian Biosimilars Congress will present multiple aspects of biosimilars from the passage of biosimilars through a decade in Asia to the latest developments in the field of biologics and biosimilars. The whole range of portfolio selection, development, regulatory requirements and marketing will be presented.

You can join your peers from around the world focused on learning about biologics and biosimilars-related advances, which is your single best opportunity to reach the largest assembly of participants from the Biosimilars community, conduct demonstrations, distribute information, meet with professionals, make a splash with new research, and receive name recognition at this 3-day event.

The congress will provide enough space for discussion, meetings and workshops in order to allow a close contact between speakers and visitors.

We are looking forward to see you in Beijing, China

Raymond Huml, MS, DVM, RAC, QuintilesIMS
Oxana Iliach, PhD, QuintilesIMS
Charu Manaktala, MD, QuintilesIMS



Welcome Message

Dear Industry Colleagues, Scientists and Friends,

As a member of the Organizing Committee I am delighted to invite you to attend the 8th Asian Biologics and Biosimilars Congress to be held from August 10-12, 2017 in Beijing, China. The Asian Biosimilars Congress 2017 brings together biopharmaceutical industry colleagues, scientists, researchers, regulatory, and clinical experts from around the globe to bring to you the cutting edge information for the development of biosimilars.

The 8th Asian Biologics and Biosimilars Congress is designed to bring forth the most up to date information for the development of biosimilars. Key aspects will include regulatory, CMC, clinical and marketing considerations, as they relate to what it will take to bring these lifesaving/life altering products to the highly regulated Western Markets.

Please join your peers from around the world for this wonderful opportunity to reach the largest assembly of participants from the Biologics/Biosimilars community, meet with thought leadership experts, share your new research, and show off your cutting edge technology at this 3-day event.

I look forward to seeing you in Beijing, China at the 8th Asian Biologics and Biosimilars Congress.

Kamali Chance

MPH, PhD, RAC

Vice President


Head, Global Biosimilars Regulatory Strategy

Biosimilars Center of Excellence

QuintilesIMS


Focused on immunogenicity and pharmacokinetics
AffinityImmuno®
is focused on biosimilars and biological immunogenicity and pharmacokinetics testing.We offer custom and off-the-shelf research and development solutions
Our products are madefor scientists by scientists. Be the first to market with our help.
www.affinityimmuno.com
In Collaboration with:
Affinity Immuno
Quality. Immuno. Biologicals.
Asian Biosimilars 2017


Keynote Speakers @ Asian Biosimilars 2017
Kamali Chance
Vice President, Head, Global Biosimilars Regulatory Strategy
Quintiles, Inc.
USA
Raymond Huml
Vice Precident
Quintiles IMS
USA
Oxana Iliach
Sr. Director
Quintiles IMS
Canada
Jianguo Yang
President / CEO, Abpro
China Division
USA
Charu Manaktala
Senior Medical Director
Quintiles IMS
India
Hossein Pakdaman
President of Iranian Neurological Association
Iran


Special Session on
Asian Biosimilars 2017
Pfizer
Biosimilars: Challenges in Safety and Risk Management
Asif Mahmood
Disease Area Cluster Lead for Biosimilars Pfizer, USA

Confreence Highlights

- Latest Biosimilars in Asian Scenario
- Biosimilars- Hatch-Waxman Act & BPCI Act
- Challenges in Developing Biosimilars
- Biosimilars Research Pipeline
- Current Developments in The Field of Biosimilars
- Pharmacovigilance of Biosimilars
- Emerging Trends in Biosimilars
- Biosimilars Market- Challenges & Prospects
- Cost Analysis of Biosimilars
- Globalization of Biosimilars
- Biosimilars Analytical Strategies
- Emerging Biosimilars in Therapeutics
- Clinical Studies on Biosimilars
- BCS & IVIVC Based Biowaivers
- Entrepreneurs Investment Meet

** Speaker Slots are Available **

Organizing Committee Members



Kamali Chance
Vice President
Quintiles, Inc.
USA



Oxana Iliach
Sr. Director
Quintiles IMS
Canada



Raymond Huml
Vice Precident
Quintiles IMS
USA



Hossein Pakdaman
Shahid Beheshti University
of Medical Sciences
Tehran, Iran



Candida Fratazzi
President
BBCR Consulting
USA



Charu Manaktala
Senior Medical Director
Quintiles IMS
India



Asif Mahmood
Disease Area Cluster
Lead for Biosimilars Pfizer
USA



Suzette DiMascio
CEO & President
CSI Specialty Group
USA




T. Santha Raju
Sr. Director & Head
MedImmune
USA



Lutz Hilbrich
Head of Biosimilars
Platform in China Shanghai,
China



Osama O. Ibrahim
Consultant Biotechnology/
Food Safety
Bioinnovation, USA



Jianguo Yang
President / CEO Abpro
China Division
USA

8th Asian Biologics and Biosimilars Congress

August 10-12, 2017 Beijing, China

Top Participating Organisations

Tentative Program

Keynote Forums

Title: FDA/EMA Current Thinking on Totality of Evidence for Development of Biosimilars

Kamali Chance, Vice President, Head, Global Biosimilars Regulatory Strategy, Biosimilars Center of Excellence, Quintiles, Inc., USA

Title: Biosimilars: Accelerating Early Clinical Development

Raymond Huml, Vice Precident, Quintiles IMS, USA

Title: Strategy for the Global Development of Biosimilars: putting it's all together

Oxana Iliach, Sr. Director, Quintiles IMS , Canada

Title: Strategic Partnership for China Biologics

Jianguo Yang, President / CEO, Abpro China Division, USA

Title: Clinical Development of Biosimilars for Western Markets: Planning for Success

Charu Manaktala, Senior Medical Director, Quintiles IMS, India

Title: Biosimilars in treatment of multiple sclerosis in Iran

Hossein Pakdaman, President of Iranian Neurological Association, Iran

Special Sessions

Title: Biosimilars: Challenges in Safety and Risk Management

Asif Mahmood, Disease Area Cluster lead for Biosimilars, Pfizer, USA

Scientific Sessions

Title: Update on biosimilars litigation in the U.S.: What if you don't want to dance?

George C. Yu, J.D., M.S., Schiff Hardin LLP, USA

Title: Challenges in Assessing Therapeutic Equivalence of Nano-Similars

Beat Flühmann, Director Vifor Pharma Ltd, Switzerland

Title: Biosimilar Globalization- A silver lining in untested waters! Biosimilars in China: balance of risks and opportunities.

Candida Fratazzi MD, President, BBCR Consulting, USA

Title: The role of regulatory policies in relation to the local biosimilars production

Gustavo H. Marin, PhD, UNLP-CONICET, Argentina

Title: Practical Considerations in Clinical Strategy to Support the Development of Biologics Device Combination Products

Zhaoyang Li, Director, Sanofi, USA

Title: Current status in the development of Biosimilar Market in LATAM region: An update on market barriers, opportunities and regulatory requirements

Edgar Mauricio Rubio Rubio, Pharmacist- Business Development Manager- Biopas- Latam region, USA

Title: Biosimilars in the UK's NHS: Attitudes, appetites and acceptance

Divya Chadha Manek, Head of Commercial Business Development, NIHR Clinical Research Network, National Institute for Health Research

Title: From Neuromodulation to Drug Discovery and Treatment

Luis Ulloa, Professor of Surgery at New Jersey Medical School at Rutgers, the state University of New Jersey

Title: Theodor Bilharz Research Institute Therapeutic products and health tools

Ismaeil Mohamed, Professor, Ministry of Higher Education and Scientific Research, Egypt

Title: Expression of with Shiga like toxin (SLT) fused to vascular endothelial growth factor (VEGF) in E coli for targeting angiogenesis

Osama O. Ibrahim Ph.D.,Consultant Biotechnology, Bio Innovation LLC, USA

Title: Medicines distributions and financing alternatives

Abdeen M Omer, PhD, Khartoum, Sudan

Title: Some Considerations about Biosimlar Safety

Samer M. Al-Hulu, PhD, Al-Qasim Green University , Iraq

Title:The study of Antimicrobial and anti-Alzheimer's effects of turmeric extract based on amyloid nano-bio-fibrils formation inhibition method

Amir Arasteh, Assistant Professor of Biochemistry, Department of biology, Rasht Branch, Islamic Azad University, Rasht, Iran

Title: Evaluation The Cytotoxicity Of An Oscillatoria Sp. Extract On Breast Cancer Cell Line (Mcf-7) And Assessment Of Noxa Gene Expression

Ali Salehzadeh, Department of Biology, Rasht Branch, Islamic Azad University, Rasht, Iran

Title: Significance of stability and temperature excursion studies for Biologistics

Rajiv Dua, Site ATS Head, Sun Pharmaceuticals Ltd, India

Title: Global Status of Biosimilars & Prospects in Asia

Md Abu Zafor Sadek, Institute of Business Administration, University of Dhaka, Bangladesh

Title: Bioassay-Directed Isolation Of Hypotensive Alkaloids From Holarrena Pubescens

Aftab Khalid, H.E.J. Research Institute of Chemistry, University of Karachi, Pakistan

Title: Heterogeneity of Monoclonal Antibody and Challenges in Developing Biosimilar of it

Sunit Maity, PhD, Zumutor, India

Speaker Slots Available

NOTE: Program is subject to change with final allotment of the speaker slots



Previous Speakers



Patrick Lucy
Pfenex Inc
USA



Alex Brill
American Enterprise Institute
USA



Jill Myers
Fortress Biotech
USA



Yahua (Jenny) Chen
Wolf, Greenfield & Sacks, P.C,
USA



Milind Antani
Nishith Desai Associates
India



William Sarraille
Sidley Austin LLP
USA



Timothy Shea
Sterne, Kessler, Goldstein & Fox
P.L.L.C., USA



Denise Kettelberger
Patterson Thuente Pedersen, P.A.,
USA



Gregory Glover
Principal at Pharmaceutical Law
Group PC, USA



Chris Leintz
Pfizer
USA



Subir Roy
Novartis
India



Sunit Maity
Zumutor Biologics
India



Mark Emalfarb
Dyadic International, Inc.,
USA



Vivek morya
Centre for policy research
India




Abdel Halim Harrath
King Saud University
Saudi Arabia



Neil Schauer
Schauer Biologics Consulting, LLC,
USA

Previous Speakers



Sarfaraz K. Niazi
Adello Biologics, LLC
USA



Angela Furlanetto
DLA Piper (Canada) LLP
Canada



Ronald A Rader
Biotechnology Information Institute,
USA



Raymond A Huml
QuintilesIMS
USA



James Harris
Healthcare Economics LLC
USA



Lisa Mueller
Women In Bio
USA



Raj Dave
Pillsbury Winthrop Shaw Pittman
LLP, USA



Kerisha Bowen
Dentons US LLC
USA



Abe Hershkovitz
Hershkovitz & Associates, PLLC
Usa



Nigel Rulewski
Quintiles
USA



András Guttman
University of Pannonia
Hungary SCIEX, USA



Sumant Chaubey
Bills Biotech
India



Andreu Soldevila
CEO LeanBioPro
Spain



Tom Carver
J A Kemp - Patent and Trade Mark
Attorneys, UK



Christoph Volpers
Senior Patent Consultant at Michalski
& Hüttermann, Germany




Wolfgang Rehmann
Taylor Wessing
Germany

Previous Speakers



Marcus Mreyen
Protagen Protein Services, GmbH,
Germany



Min Zhang
AstraZeneca
USA



Fiona M Greer
SGS Life Sciences
United Kingdom



Volker Schellenberger
Amunix Operating Inc.,
USA



Alan L. Epstein
USC Keck School of Medicine
USA



Upendra Nagaich
Amity Institute of Pharmacy
India



Gene Ransom
CEO MedChi, The Maryland State
Medical Society, USA



Gordon Bolger
Nucro-Technics Inc.,
Canada



Adetunji Olawale
Osun State Polytechnic
Nigeria



Afshin Safavi
BioAgilytix Labs
USA



Mariana Babayeva
Touro College of Pharmacy
USA



Andy Upsall
Antibody Analytics
United Kingdom



Samantha (Little) Howard
Covance Clinical Research Unit, Inc.,
United Kingdom



Kamali Chance
Quintiles, IMS
USA



Mario DiPaola
Blue Stream Laboratories, Inc
USA



Francesco Marchesi
Regina Elena National Cancer
Institute, Italy

Previous Speakers



Candida Fratazzi
BBCR Consulting
USA



Krishna Menon
Cellceutix
USA



Daniel Galbraith
BioOutsource Ltd
United Kingdom



Siddhartha Roy
Bose Institute
India




Noelle Sunstrom
NeuClone Pty Ltd
Australia



Dipti Gulati
PJI Biotech
USA



Alexander Pitters
Kaiser Optical Systems
France



Laszlo Endrenyi
University of Toronto
Canada



Christina Vessely
Biologics Consulting
USA



Ruediger Jankowsky
Cinfa Biotech GmbH
Germany



Christelle Dagoneau
Catalent Biologics
USA



Aparna Kasinath
Syngene International
India

Why to Attend???

Join your peers around the world focused on learning about Biologics and Biosimilars related advances, which is your single best opportunity to reach the largest assemblage of participants from the Biosimilars community, conduct demonstrations, distribute information, meet with current and potential professionals, make a splash with a new research works, and receive name recognition at this 3-day event. World-renowned speakers, the most recent research, advances, and the newest updates in Biologics and Biosimilars are hallmarks of this conference.

At Asian Biosimilars 2017 meet your target audiences from around the world focused on learning about biologics and biosimilars. This conference would be your single best opportunity to reach the largest assemblage of participants from the biologics and biosimilars community.

Abstract Information: Oral / Poster Presentation Guidelines

Oral Presentations are generally split into TWO categories, as follows:

1. Plenary Lectures
   - Each Plenary lecture is 25 minutes in length and comprises one presentation. We recommend you plan to present for approximately 20 minutes with 5 minutes for questions/discussion.
   - Where Plenary Lectures are presented as debates, each of two speakers should plan to present for 20 minutes, allowing five minutes for closing questions and conclusions. We recommend that invited speakers communicate in advance of the Moderator so that presentations may be coordinated.
2. Oral Sessions
   - Each Oral Session is 60 minutes in length and comprises two presentations, of 30 minutes each. We recommend that you plan to present for approximately 15 minutes, allowing time for questions/discussion at the end of the presentation.

Please prepare you presentation in 16:9 format (screen are in format 16:9). We recommend you to save your PowerPoint presentation using PPT(X) format instead of PPS.

A technician is available in every session room to provide assistance when needed. Due to the online presentation system, all speakers are kindly requested to use provided PC onsite. Please be present in the session room 15 minutes prior the start of your session and follow the instructions from the Chairs and/or technician. During your presentation a remote control will be available for controlling your presentation. Please observe the time allotted to you as you will not be permitted to speak for longer time. At the end of the Congress, all presentations will be deleted from the presentation system and computers on-site.

Speaker Preview Room

All speakers are asked to upload their presentation at the Speaker Preview Room (located in the Registration area) at least one hour before the beginning of the session or the day before in case of a morning session.

Poster Guidelines

The poster exhibition will be an integral part of Med Pharma Congress.

The poster exhibition will be located on the exhibition area of the congress centre. The area will be clearly signposted from the registration area.

Technical Instructions:

- Posters must be prepared in Portrait style.
- Please DO NOT prepare a landscape poster
- The dimensions should be 100 cm high by 70 cm wide
- Posters should be attached to the boards with stickers, which you will be supplied to the organizers.
- Poster session schedule Posters will be displayed and presented in session.

Please plan to be at your poster and available to answer questions from delegates at the time of your assigned poster session. Posters will be displayed according to the POSTER numbers given by the organizers and will be grouped by sub topic.

Young Researchers Forum

The Young Researchers Forum offers young researchers the possibility to meet and discuss research topics and methodologies, share and develop ideas, learn from each other and gain knowledge from senior researchers.

Young Researcher Sessions are organized at the Med Pharma Congress, to provide a unique platform for Young Researchers/Investigators for presenting latest research projects with an in-depth analysis. Young Investigators (e.g. Post-Graduate students, Post-doctoral fellows, Trainees, Junior faculty) are the focus of this event. Participants should be below the age of 33 years. All submissions must be in English.

The prize winning papers will be considered for publication in the international journals once the paper is subjected to standard review procedures.

For further information please contact: biosimilarsasia@pharmaceuticalconferences.org



Registration Information

How To Register

Website: http://biosimilars-biologics.pharmaceuticalconferences.com/asiapacific//registration.php

Registration Fees

- Early registration fee: $799
- (SAVE $100.00 — DEADLINE: May 25, 2017)
- Regular registration fee: $899
- SAVE $100.00 — February 28, 2017 through June 27, 2017)
- Late registration fee: $999
- Discounts on Group Registrations
- Student Registration: $249
- Young Researchers Forum Fee: 399$

Cancellation Policy

Cancellations must be received in writing 60 days prior to the meeting and are subject to a $100 processing fee. Refunds will not be granted after April 03, 2017, nor will they be given for no-shows. Please email cancellations to biosimilarsasia@pharmaceuticalconferences.org

Accommodations

Double Tree by Hilton Beijing
168 Guang An Men Wai Avenue Xi Cheng District,
Beijing 100055
China

To make reservations and ensure that you will have a hotel room at the same location as the conference, please choose your package and register at http://biosimilars-biologics.pharmaceuticalconferences.com/asiapacific//registration.php

Payments

We accept Visa, Master Card, American Express and checks. If paying by credit card, please utilize our online registration site located at http://biosimilars-biologics.pharmaceuticalconferences.com/asiapacific//registration.php

If you wish to pay by check, please contact biosimilarsasia@pharmaceuticalconferences.org

For more information:

Questions? Contact 1 (800) 216 6499 or inquiries: biosimilarsasia@pharmaceuticalconferences.org

Register now at http://biosimilars-biologics.pharmaceuticalconferences.com/asiapacific//

Stay Connected Before, During and After the Event!

Program

Day 1: August 10, 2017

Opening Ceremony

Conference Souvenir Launch
New Perspective frontiers in the area of Biologics and Biosimilars
Keynote Forum (& Exhibitions Full day)
(Panel discussions and Reviews)
Coffee Break: Networking & Refreshments
Group Photo

Speaker Forum

Sessions Chair's Introduction
Track 1: Latest Biosimilars in Asian Scenario
Track 2: Biosimilars- Hatch-Waxman Act & BPCI Act
Track 3: Challenges in Developing Biosimilars
Track 4: Biosimilars Research Pipeline
Track 5: Current Developments in The Field of Biosimilars
Panel discussions and Reviews

Lunch Break

Young Research Forum
(Panel discussions and Reviews)
Coffee Break: Networking & Refreshments
B2B Meetings
Certificates Felicitation by the organizing Committee

Day 2: August 11, 2017

Introduction

Keynote Forum (& Exhibitions Full day)
(Panel discussions and Reviews)
Coffee Break: Networking & Refreshments

Speaker Forum

Sessions Chair's Introduction
Track 6: Pharmacovigilance of Biosimilars
Track 7: Emerging Trends in Biosimilars
Track 8: Biosimilars Market- Challenges & Prospects
Track 9: Cost Analysis of Biosimilars
Track 10: Globalization of Biosimilars
Panel discussions and Reviews

Lunch Break

Young Research Forum
(Panel discussions and Reviews)
Coffee Break: Networking & Refreshments
B2B Meetings
Certificates Felicitation by the organizing Committee

Day 3: August 12, 2017

Introduction

Keynote Forum (& Exhibitions Full day)
(Panel discussions and Reviews)
Coffee Break: Networking & Refreshments

Speaker Forum

Sessions Chair's Introduction
Track 11: Biosimilars Analytical Strategies
Track 12: Emerging Biosimilars in Therapeutics
Track 13: Clinical Studies on Biosimilars
Track 14: BCS & IVIVC Based Biowaivers
Track 15: Entrepreneurs Investment Meet
Panel discussions and Reviews
Young Research Forum
(Panel discussions and Reviews)

Lunch break

Speaker Sessions (Cont...)
Poster Sessions Evaluation by the Committee
Refreshments
Award Ceremony
Felicitation of the best poster awards

Closing Ceremony



Glimpses of Biosimilars 2016













Media Partners @ Asian Biosimilars 2017

Plan your Trip to Beijing
7 UNESCO World Heritage Sites


Forbidden City



Grand Canal



Great Wall



Ming Tombs



Summer Palace




Temple of Heaven



Zhoukoudian



Forbidden City



About Beijing

Beijing (formerly Romanized as Peking) is the capital of the People's Republic of China and the world's third most populous city proper. It is also one of the world's most populous capital cities. Beijing is the second largest Chinese city by urban population after Shanghai and is the nation's political, cultural, and educational center. It is home to the headquarters of most of China's largest state-owned companies, and is a major hub for the national highway, expressway, railway, and high-speed rail networks. The Beijing Capital International Airport is the second busiest in the world by passenger traffic. The city's subway network is among the longest and busiest in the world. The city is renowned for its opulent palaces, temples, parks, gardens, tombs, walls and gates, and its art treasures and universities have made it a center of culture and art in China.

Beijing has seven UNESCO World Heritage Sites – the Forbidden City, Temple of Heaven, Summer Palace, Ming Tombs, Zhoukoudian, as well as parts of the Great Wall and the Grand Canal. Beijing hosted the 2008 Summer Olympics and was chosen to host the 2022 Winter Olympics, which will make it the first city to ever host both events.

Beijing's primary airport is the Beijing Capital International Airport (IATA: PEK) about 20 kilometers (12 mi) northeast of the city center. The airport is the second busiest airport in the world after Hartsfield-Jackson Atlanta International Airport. After renovations for the 2008 Olympics, the airport now boasts three terminals, with Terminal 3 being one of the largest in the world. Most domestic and nearly all international flights arrive at and depart from Capital Airport. It is the main hub for Air China and a hub for China Southern and Hainan Airlines. The airport links Beijing with almost every other Chinese city with regular air passenger service.

Contact Details

http://biosimilars-biologics.pharmaceuticalconferences.com/asiapacific

Submit your abstract online at:

http://biosimilars-biologics.pharmaceuticalconferences.com/asiapacific/abstract-submission.php

Register online:

http://biosimilars-biologics.pharmaceuticalconferences.com/asiapacific/registration.php

